Clinical Trials | December 09, 2025
Kelun-Biotech and Crescent Biopharma forge strategic oncology partnership
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
MRI is particularly valuable in pediatric care due to its non-invasive nature
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
LANXESS Biosecurity Solutions aims to deliver “advanced disinfection and hygiene solutions to support Indian farmers in maintaining healthier and safer farm environments
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
Subscribe To Our Newsletter & Stay Updated
